Biospectal debuts new Healthtech at CES 2022 to reduce mortality worldwide

Biospectal, the remote patient monitoring and biosensing software company, debuts Biodisc™, a stand-alone, sleekly-designed, all-in-one, blood pressure monitoring device, and announces the public beta launch of Biospectal OptiBP™ for iOS at CES 2022. OptiBP for iOS will be available in the U.S., U.K., France, Germany, Spain and Switzerland, and follows the public beta launch of OptiBP for Android at CES 2021.

“Our mission is to democratize access to blood pressure monitoring and management globally. Our software-only approach with the Biospectal OptiBP app enables embodiment in different devices, and is now available in public beta for both Android and iOS users,” said Biospectal CEO and co-founder, Eliott Jones. “The Biospectal OptiBP app has the ability to turn the global network of smartphones into a medical-grade blood pressure monitoring platform. Our goal with Biodisc is to expand OptiBP’s reach via additional touchpoints and use cases for blood pressure monitoring in hospitals, clinics, work and the home environment. We want to make Biodisc an easily accessible, unintimidating, natural daily companion on your nightstand, desk, or countertop, inviting you to quickly capture your blood pressure regularly with no disruption to your daily routine. Biodisc is particularly well suited for people who are less comfortable with smartphone technology or complicated gadgets.”

Providing easy access to blood pressure monitoring reduces mortality worldwide.